Dual checkpoint blockade with nivolumab and relatlimab (anti-PD-1 + anti-LAG-3) has demonstrated significant antitumor efficacy in melanoma, as established in the RELATIVITY-047 trial and subsequent reviews [3], but may potentiate complex cutaneous toxicity. Here, LAG3 is linked to melanoma.